Xarelto (Rivaroxaban) Patent Expiration, LOE Window & CMS Spending

Xarelto (Rivaroxaban) by Johnson & Johnson: FDA Orange Book LOE 2034-08-17, 18 AB generics, $6.74B 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorJohnson & Johnson
FDA Application & PathwayN022406 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2034-08-17
Orange Book Patents (*PED Extensions)2 patents (1 *PED)
Active AB-Rated Generic Competitors18
2024 CMS Total Public Spend$6.74B
2024 Medicare Part D Spend$6.23B
2024 Medicaid Spend$506.8M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Johnson & Johnson across sibling Meru public-data platforms.